Skip to main content
DaShenLin Pharmaceutical Group Co., Ltd. logo

DaShenLin Pharmaceutical Group Co., Ltd. - Investor Relations & Filings

Listed IPO Jul 2017
Ticker · 603233 ISIN · CNE100002RG2 LEI · 300300TO4U1GUOTTHK82 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,450 across all filing types
Latest filing 2026-07-20 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603233 · 1 venue

Key figures FY2024

Period ended 2024-12-31 · CNY
Headline annual figures for DaShenLin Pharmaceutical Group Co., Ltd., fiscal year 2024, reported in CNY, with the source filing for each figure.
Total Revenues CNY 264.97B per the Audit Report / Information filed 2025-06-27
Net Income CNY 9.80B per the Audit Report / Information filed 2025-06-27
Total Assets CNY 264.40B per the Audit Report / Information filed 2025-06-27
Total Equity CNY 81.38B per the Audit Report / Information filed 2025-06-27
Cash from Ops CNY 31.06B per the Audit Report / Information filed 2025-06-27

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About DaShenLin Pharmaceutical Group Co., Ltd.

https://www.dslyy.com

DaShenLin Pharmaceutical Group Co., Ltd. is a large-scale enterprise specializing in the retail and distribution of pharmaceutical and health-related products. The company operates an extensive network of pharmacies, providing a wide range of products including prescription medications, over-the-counter drugs, traditional Chinese medicine, medical devices, and nutritional supplements. Beyond retail operations, the group is involved in pharmaceutical manufacturing, wholesale distribution, and logistics management. It emphasizes professional pharmaceutical services, offering health consultations and chronic disease management to its customers. By leveraging an integrated supply chain and digital health platforms, the company provides comprehensive healthcare solutions and improves accessibility to medical supplies.

Recent filings

Filing Released Lang Actions
大参林医药集团股份有限公司关于公司2025年年度报告问询函的回复公告
Regulatory Filings
2026-07-20 Chinese
天健会计师事务所（特殊普通合伙）关于大参林医药集团股份有限公司2025年年度报告问询函专项说明
Regulatory Filings
2026-07-20 Chinese
大参林医药集团股份有限公司可转债转股结果暨股份变动公告
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement regarding the conversion of convertible bonds into company shares and the resulting change in the company's total share capital. This type of filing is specifically related to capital structure changes and share issuance resulting from debt conversion, which falls under the 'Share Issue/Capital Change' category.
2026-07-01 Chinese
大参林医药集团股份有限公司公开发行可转换公司债券受托管理事务报告（2025年度）
Regulatory Filings Classification · 95% confidence The document is a 'Trustee Management Report' (受托管理事务报告) for a convertible bond issued by a company. This type of report is a standard regulatory requirement for bond issuers, prepared by the bond trustee (in this case, China Securities Co., Ltd.) to provide an annual update on the bond's status, the issuer's financial health, and compliance with bond covenants. It is a specific type of regulatory filing related to debt instruments, which falls under the 'Regulatory Filings' category as it does not fit into the specific financial report categories like 10-K or IR, and is not a simple announcement. FY 2025
2026-06-29 Chinese
大参林医药集团股份有限公司关于对子公司提供担保的进展公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from '大参林医药集团股份有限公司' (DaShenLin Pharmaceutical Group Co., Ltd.) regarding the progress of providing guarantees for its subsidiaries. It details the specific amounts, the beneficiaries, the internal decision-making process (board and shareholder approval), and the financial status of the subsidiaries involved. This type of corporate disclosure regarding financial guarantees, debt support, or capital structure commitments falls under the 'Regulatory Filings' (RNS) category as it is a standard regulatory announcement required by stock exchanges for listed companies, and it does not fit into the more specific categories like Earnings Release, Annual Report, or M&A.
2026-06-25 Chinese
大参林医药集团股份有限公司关于“大参转债”2026年跟踪评级结果的公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (681 characters) regarding the credit rating results for the company's convertible bond ('大参转债'). It explicitly states that the full rating report is available on the Shanghai Stock Exchange website, which aligns with the 'Menu vs Meal' rule for Report Publication Announcements (RPA). While it discusses credit ratings, it is not the full audit or rating report itself, but rather a notice of the publication of that report.
2026-06-24 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.